These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29438046)

  • 41. Interferon beta, birth weight and pregnancy in multiple sclerosis.
    Hellwig K; Agne H; Gold R
    J Neurol; 2009 May; 256(5):830-1. PubMed ID: 19240959
    [No Abstract]   [Full Text] [Related]  

  • 42. Exposure to natalizumab during pregnancy and lactation is safe - No.
    Airas L
    Mult Scler; 2020 Jul; 26(8):889-891. PubMed ID: 32508200
    [No Abstract]   [Full Text] [Related]  

  • 43. The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
    Robier C; Amouzadeh-Ghadikolai O; Bregant C; Diez J; Melinz K; Neubauer M; Quasthoff S
    Mult Scler; 2014 Aug; 20(9):1269-72. PubMed ID: 24493472
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation.
    Proschmann U; Haase R; Inojosa H; Akgün K; Ziemssen T
    Front Immunol; 2021; 12():715195. PubMed ID: 34512637
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exposure to natalizumab during pregnancy and lactation is safe - Yes.
    Landi D; Marfia GA
    Mult Scler; 2020 Jul; 26(8):887-889. PubMed ID: 32508253
    [No Abstract]   [Full Text] [Related]  

  • 46. Parenthood and immunomodulation in patients with multiple sclerosis.
    Hellwig K; Haghikia A; Gold R
    J Neurol; 2010 Apr; 257(4):580-3. PubMed ID: 19936821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.
    Federle L; Puthenparampil M; Stenta G; Paolo G; Francesco P
    Mult Scler Relat Disord; 2019 May; 30():262-264. PubMed ID: 30851640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Smokers run increased risk of developing anti-natalizumab antibodies.
    Hedström AK; Alfredsson L; Lundkvist Ryner M; Fogdell-Hahn A; Hillert J; Olsson T
    Mult Scler; 2014 Jul; 20(8):1081-5. PubMed ID: 24311118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Are there adverse effects of periconceptional spermicide use?
    Mills JL; Reed GF; Nugent RP; Harley EE; Berendes HW
    Fertil Steril; 1985 Mar; 43(3):442-6. PubMed ID: 3979584
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
    Link J; Ramanujam R; Auer M; Ryner M; Hässler S; Bachelet D; Mbogning C; Warnke C; Buck D; Hyldgaard Jensen PE; Sievers C; Ingenhoven K; Fissolo N; Lindberg R; Grummel V; Donnellan N; Comabella M; Montalban X; Kieseier B; Soelberg Sørensen P; Hartung HP; Derfuss T; Lawton A; Sikkema D; Pallardy M; Hemmer B; Deisenhammer F; Broët P; Dönnes P; Davidson J; Fogdell-Hahn A;
    PLoS One; 2017; 12(2):e0170395. PubMed ID: 28170401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Oshima Y; Tanimoto T; Yuji K; Tojo A
    Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A decade of natalizumab and PML: Has there been a tacit transfer of risk acceptance?
    Clifford DB; Yousry TA; Major EO
    Mult Scler; 2017 Jun; 23(7):934-936. PubMed ID: 27679459
    [TBL] [Abstract][Full Text] [Related]  

  • 53. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
    Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
    J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
    Akatani R; Chihara N; Katanazaka K; Ueda T; Sekiguchi K; Matsumoto R
    Rinsho Shinkeigaku; 2019 Aug; 59(8):536-540. PubMed ID: 31341130
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M; Schiavetti I; De Mercanti SF; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Ghezzi A; Bianchi A; Salemi G; Realmuto S; Sola P; Vitetta F; Cavalla P; Paolicelli D; Trojano M; Sormani MP; Durelli L
    JAMA Neurol; 2014 Aug; 71(8):954-60. PubMed ID: 24977406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020.
    Moccia M; Affinito G; Fumo MG; Giordana R; Di Gennaro M; Mercogliano M; Carotenuto A; Petracca M; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
    J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):689-697. PubMed ID: 37068930
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study.
    Eisele P; Szabo K; Ebert A; Platten M; Gass A
    J Neuroimaging; 2019 Mar; 29(2):190-192. PubMed ID: 30485572
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes.
    Bérard A; Zhao JP; Shui I; Colilla S
    Ann Rheum Dis; 2018 Apr; 77(4):500-509. PubMed ID: 29222350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study.
    Weber-Schoendorfer C; Chambers C; Wacker E; Beghin D; Bernard N; ; Shechtman S; Johnson D; Cuppers-Maarschalkerweerd B; Pistelli A; Clementi M; Winterfeld U; Eleftheriou G; Pupco A; Kao K; Malm H; Elefant E; Koren G; Vial T; Ornoy A; Meister R; Schaefer C
    Arthritis Rheumatol; 2014 May; 66(5):1101-10. PubMed ID: 24470106
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
    Schwab N; Schneider-Hohendorf T; Hoyt T; Gross CC; Meuth SG; Klotz L; Foley JF; Wiendl H
    Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.